Rising Quarterly Sales Stocks to Buy in November 2026: 5 Names on the Watchlist
- November 5, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
ITC Hotels Rs 173.29. Ajanta Pharma Rs 3,317. Global Health Rs 1,402. Olectra Rs 1,059. KFin Technologies Rs 896.80. NSE closing prices, 4 Nov 2026.
Quick Answer
Five rising quarterly sales stocks to buy on the November 2026 watchlist are ITC Hotels, Ajanta Pharma, Global Health, Olectra Greentech and KFin Technologies. All five grew revenue in their latest full year, and all five also grew net profit. ITC Hotels has the lowest P/E at 36.63, while Ajanta Pharma leads on return on equity at 23.33%. Check each valuation against your own risk appetite before acting.
The rising quarterly sales stocks to buy in November 2026 start with five listed names: ITC Hotels, Ajanta Pharma, Global Health, Olectra Greentech and KFin Technologies. Rising quarterly sales stocks are companies whose revenue in the latest quarter was well above the same quarter a year earlier.
This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these rising quarterly sales stocks to buy to a portfolio. All prices are NSE closing prices of 4 November 2026, and financials come from company filings.
Click Here – Get Free Investment Predictions
Which Are the Best Rising Quarterly Sales Stocks to Buy in November 2026?
The best rising quarterly sales stocks to buy in November 2026 for a watchlist are ITC Hotels, Ajanta Pharma, Global Health, Olectra Greentech and KFin Technologies. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.
| Company | CMP (Rs) | Market Cap | P/E | ROE | Dividend Yield |
|---|---|---|---|---|---|
| ITC Hotels | 173.29 | Rs 34,414 crore | 36.63 | 7.94% | 0.61% |
| Ajanta Pharma | 3,317 | Rs 43,234 crore | 38.10 | 23.33% | 0.81% |
| Global Health | 1,402 | Rs 34,933 crore | 63.25 | 14.05% | 0.04% |
| Olectra Greentech | 1,059 | Rs 8,021 crore | 44.52 | 14.46% | 0.06% |
| KFin Technologies | 896.80 | Rs 14,910 crore | 42.76 | 21.47% | 1.39% |
On valuation, ITC Hotels, Ajanta Pharma, Global Health and KFin Technologies sit close to it; Olectra Greentech carries a premium. Valuation is the first filter for any rising quarterly sales stocks to buy list, and it is covered again in the risk section.
Why These Rising Quarterly Sales Stocks to Buy Are in Focus
In this list, latest-quarter revenue grew between roughly 25% and 64% year on year, and FY26 revenue grew for every company. The list covers the hotel arm of ITC, a branded generics pharma company, the company behind Medanta hospitals, an electric bus maker and a registrar and technology services company. Investors comparing the best rising quarterly sales stocks in India usually check whether strong sales are repeating and reaching profit.
ITC Hotels: The ITC Hotels Chain Among Rising Quarterly Sales Stocks to Buy
ITC Hotels is the hotel arm of ITC, with premium brands such as ITC Hotels and Welcomhotel. Its market capitalisation is Rs 34,414 crore, the share price is Rs 173.29 and the P/E of 36.63 compares with an industry P/E of 37.68.
Over FY26, net profit rose 28.8% to Rs 821 crore on revenue of Rs 4,331 crore, which was up 19.4%. The latest quarter, the September 2026 quarter, brought revenue of Rs 1,106 crore, up 25.0% year on year, and net profit of Rs 203 crore, up 52.0%.
Return on equity is 7.94%, debt-to-equity is 0.01, and the dividend yield is 0.61%. Promoters hold 39.85%, foreign institutions 11.63% and domestic institutions 17.88% as of September 2026. A point to keep in view: return on equity is a modest 7.94%.
Ajanta Pharma: The Branded Generics Specialist Among Rising Quarterly Sales Stocks to Buy
Ajanta Pharma is a branded generics company with a strong presence in dermatology, ophthalmology and cardiology in India, Africa and Asia. The stock trades at Rs 3,317 with a market capitalisation of Rs 43,234 crore and a P/E of 38.10, against an industry P/E of 37.65.
FY26 revenue rose 18.6% to Rs 5,625 crore and net profit rose 14.7% to Rs 1,056 crore. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit grew 30.9% to Rs 334 crore.
Return on equity is 23.33%, debt-to-equity is 0.06, and the dividend yield is 0.81%. Promoters hold 63.47%, foreign institutions 7.63% and domestic institutions 21.94% as of September 2026. Domestic institutional holding has risen from 17.90% to 21.94% over the last year.
Check Rising Quarterly Sales Stocks Live on the Univest Screener
Global Health: The Medanta Operator Among Rising Quarterly Sales Stocks to Buy
Global Health is the company behind Medanta hospitals, with large multi-speciality hospitals in north India. At Rs 1,402, the stock has a market capitalisation of Rs 34,933 crore and trades at 63.25 times earnings, while the industry P/E is 61.50.
Reported numbers show FY26 revenue of Rs 4,509 crore, up 19.6% year on year, with net profit at Rs 554 crore, up 15.1%. The June 2026 quarter added revenue of Rs 1,326 crore (up 26.1%) and net profit of Rs 157 crore (down 1.1%).
Return on equity is 14.05%, debt-to-equity is 0.30, and the dividend yield is 0.04%. Promoters hold 33.00%, foreign institutions 9.91% and domestic institutions 17.01% as of September 2026. Domestic institutional holding has risen from 12.98% to 17.01% over the last year. A point to keep in view: at a P/E of 63.25, expectations are already high.
Olectra Greentech: The Electric Bus Maker Among Rising Quarterly Sales Stocks to Buy
Olectra Greentech is an electric bus manufacturer. Its market capitalisation is Rs 8,021 crore, the share price is Rs 1,059 and the P/E of 44.52 compares with an industry P/E of 23.77.
Over FY26, net profit rose 29.0% to Rs 180 crore on revenue of Rs 2,327 crore, which was up 28.2%. The latest quarter, the June 2026 quarter, brought revenue of Rs 578 crore, up 63.8% year on year, and net profit of Rs 26.7 crore, up 2.4%.
Return on equity is 14.46%, debt-to-equity is 0.31, and the dividend yield is 0.06%. Promoters hold 50.02%, foreign institutions 7.34% and domestic institutions 0.60% as of September 2026.
KFin Technologies: The Registrar and Technology Name Among Rising Quarterly Sales Stocks to Buy
KFin Technologies is a registrar and technology services company for mutual funds and issuers. The stock trades at Rs 896.80 with a market capitalisation of Rs 14,910 crore and a P/E of 42.76, against an industry P/E of 42.66.
FY26 revenue rose 19.1% to Rs 1,344 crore and net profit rose 3.3% to Rs 344 crore. In the September 2026 quarter, revenue grew 28.1% year on year to Rs 410 crore, while net profit grew 7.5% to Rs 100 crore.
Return on equity is 21.47%, and the dividend yield is 1.39%. Promoters hold 14.06%, foreign institutions 20.07% and domestic institutions 37.55% as of September 2026. Domestic institutional holding has risen from 24.80% to 37.55% over the last year.
Download the Univest iOS App or Univest Android App to track these rising quarterly sales stocks live and get daily stock recommendations.
Growth Snapshot: Latest Full Year and Latest Quarter
The table compares year-on-year growth in revenue and net profit for all five rising quarterly sales stocks, using filed results.
| Company | Full-Year Revenue Growth | Full-Year Profit Growth | Latest Quarter | Quarter Revenue Growth | Quarter Profit Growth |
|---|---|---|---|---|---|
| ITC Hotels | 19.4% | 28.8% | Sep 2026 | 25.0% | 52.0% |
| Ajanta Pharma | 18.6% | 14.7% | Jun 2026 | 27.7% | 30.9% |
| Global Health | 19.6% | 15.1% | Jun 2026 | 26.1% | -1.1% |
| Olectra Greentech | 28.2% | 29.0% | Jun 2026 | 63.8% | 2.4% |
| KFin Technologies | 19.1% | 3.3% | Sep 2026 | 28.1% | 7.5% |
Factors That Move Rising Quarterly Sales Stocks to Buy
Four factors tend to drive rising quarterly sales stocks, and each one is worth checking before a purchase.
- Sales momentum: Check whether growth repeats across quarters.
- Profit follow-through: Sales growth should reach earnings.
- Seasonality: Some quarters are naturally stronger.
- Valuation: Strong sales are often priced in.
Risks to Keep in Mind Before Buying Rising Quarterly Sales Stocks
The first risk is that one strong quarter does not make a trend, and seasonal or order-based sales can swing. The second is valuation, since several of these names trade at premium multiples. Check the next two results before drawing conclusions.
On the numbers, Global Health trades at the highest P/E on this list at 63.25, so its earnings need to keep growing to support the price. Rising Quarterly Sales stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.
How to Choose Rising Quarterly Sales Stocks to Buy
- Compare with last year: Look at year-on-year change.
- Look at profit: Revenue and profit should move together.
- Check order books: Bus and hotel sales can be lumpy.
- Study valuation: Compare P/E with the industry.
How to Invest in Rising Quarterly Sales Stocks
- Shortlist two or three companies from this list that match your risk appetite.
- Open the Univest Screener and compare P/E, ROE and debt for each stock.
- Check the latest quarterly results and shareholding pattern on NSE or BSE.
- Decide an amount you can hold for three to five years and split it into two or three purchases.
- Review the holding after every quarterly result instead of reacting to daily price moves.
Conclusion
ITC Hotels offers the lowest P/E on this list at 36.63, Ajanta Pharma has the highest return on equity at 23.33%, and Olectra Greentech posted the fastest net profit growth in its latest full year at 29.0%. Among the best rising quarterly sales stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these rising quarterly sales stocks to buy.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Rising Quarterly Sales Stocks to Buy
Which are the best rising quarterly sales stocks to buy in November 2026?
Ans. The five rising quarterly sales stocks on the November 2026 watchlist are ITC Hotels, Ajanta Pharma, Global Health, Olectra Greentech and KFin Technologies. ITC Hotels has the lowest P/E at 36.63, Ajanta Pharma has the highest ROE at 23.33%, and Olectra Greentech grew net profit 29.0% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.
Is Ajanta Pharma a good stock to buy from this Rising Quarterly Sales list?
Ans. Ajanta Pharma is the largest company on this list with a market capitalisation of Rs 43,234 crore and a P/E of 38.10 against an industry P/E of 37.65. Its FY26 revenue rose 18.6% and net profit rose 14.7%, with return on equity at 23.33%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.
Are these rising quarterly sales stocks expensive right now?
Ans. Valuations vary across the group. ITC Hotels trades at a P/E of 36.63, Ajanta Pharma trades at a P/E of 38.10, Global Health trades at a P/E of 63.25, Olectra Greentech trades at a P/E of 44.52, KFin Technologies trades at a P/E of 42.76, against industry multiples ranging from 23.77 to 61.50. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.
Which of these rising quarterly sales stocks pay a dividend?
Ans. Dividend yields on this list are ITC Hotels 0.61%, Ajanta Pharma 0.81%, Global Health 0.04%, Olectra Greentech 0.06%, KFin Technologies 1.39%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.
Which stock on this list has the highest return on equity?
Ans. Ajanta Pharma has the highest ROE on this list at 23.33%, followed by KFin Technologies at 21.47% and Olectra Greentech at 14.46%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.
What are the risks of investing in rising quarterly sales stocks?
Ans. The main risks are quarterly sales that swing with seasons and orders, premium valuations and the need to confirm a trend. On this list, Global Health trades at the highest P/E of 63.25, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.
How can I invest in rising quarterly sales stocks in India?
Ans. You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.
